Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rom Leidner

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
JCO Oncology Practice|November 12, 2024
Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health SystemAlexa K Dowdell, Ryan C Meng, Ann Vita, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinomaRom Leidner, Marka Crittenden, Kristina Young, et al.
JCI Insight|July 21, 2017
Multiparametric immune profiling in HPV- oral squamous cell cancerZipei Feng, Daniel Bethmann, Matthias Kappler, et al.
Nature Communications|July 15, 2018
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumorsThomas Duhen, Rebekka Duhen, Ryan Montler, et al.
International Journal of Biological Sciences|March 14, 2024
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian CancerJunping Li, Hong Hu, Hui Lian, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trialRobert L Ferris, William C Spanos, Rom Leidner, et al.
Frontiers in Immunology|December 29, 2025
Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategyHongye Tan, Noor Ul Huda Shah, Bingjia He, et al.
Oral Oncology|October 10, 2022
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neckBrian J Park, Austin K Mattox, Daniel Clayburgh, et al.
Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
JCO Oncology Practice|November 12, 2024
Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health SystemAlexa K Dowdell, Ryan C Meng, Ann Vita, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinomaRom Leidner, Marka Crittenden, Kristina Young, et al.
JCI Insight|July 21, 2017
Multiparametric immune profiling in HPV- oral squamous cell cancerZipei Feng, Daniel Bethmann, Matthias Kappler, et al.
Nature Communications|July 15, 2018
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumorsThomas Duhen, Rebekka Duhen, Ryan Montler, et al.
International Journal of Biological Sciences|March 14, 2024
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian CancerJunping Li, Hong Hu, Hui Lian, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trialRobert L Ferris, William C Spanos, Rom Leidner, et al.
Frontiers in Immunology|December 29, 2025
Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategyHongye Tan, Noor Ul Huda Shah, Bingjia He, et al.
Oral Oncology|October 10, 2022
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neckBrian J Park, Austin K Mattox, Daniel Clayburgh, et al.
Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Pageof 3